Phase II clinical trial of AZD2171 [cediranib] monotherapy in recurrent or metastatic head and neck squamous cell carcinoma patients
Phase of Trial: Phase II
Latest Information Update: 08 May 2015
At a glance
- Drugs Cediranib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 04 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 26 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Aug 2007 Status changed from initiated to recruiting.